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The most crucial reason for vascular access dysfunction in hemodialysis 
patients is stenosis caused by neointimal hyperplasia. Until now, paclitaxel 
has been shown to act as a great anti-proliferative agent and effectively 
lowers stenosis on graft-venous anastomosis sites. Dipping method allows 
us to obtain paclitaxel coated Arteriovenous (AV) expanded 
polytetrafluoroethylene (ePTFE) grafts in a quick, uniform and facile 
manner. As the whole graft surface elutes paclitaxel upon implantation by 
systemic circulation, I ought to validate how various amounts of paclitaxel 




paclitaxel for study- Control (0 ug/mm2), Group 1 (0.14ug/mm2), Group 2 
(0.28ug/mm2), Group 3 (0.51ug/mm2), Group4 (1.11ug/mm2), and Group 5 
(2.22ug/mm2). This work uncovers that in general, paclitaxel coated grafts 
revealed high level of patency compared to the control group in which grafts 
were almost all occluded, however; at high concentrations of paclitaxel, the 
surrounding tissue and the graft retained little affinity. I attribute this for a 
foreign body response and hence arise necessity to tune the amount of 
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1.1 .1 Different types of vascular access 
Patients with chronic renal disease requiring hemodialysis therapy need a 
stable vascular access in order to withdraw blood at a rate of approximately 
300mL/min from the patient. This rate is higher than and lower than the rate 
of blood flow in vein and artery respectively. In most cases, patients 
requisite a permanent vascular access rather than a temporary means, thus it 
is necessary to connect the artery and the vein for the efficient hemodialysis. 
Types of the permanent access for a long-term dialysis are mainly arterio-
venous (AV) fistulas, and AV grafts. Different outcomes, degrees of 
patency, and types of complications arise from each type of the vascular 
access 1, 2.  
1.1.2 Arteriovenous Fistula 
AV fistula can be categorized into two subgroups based on the use of 
materials. The autogenous AV fistula is constructed only with native 
material and the non-autogenous AV fistula is utilized alternatively when 
there are insufficient or unavailable veins to build a vascular access. The 
non-autogenous AV fistula is also known as AV graft as surgeons rely on 
graft materials. If possible, AV graft implantation is avoided due to 
relatively lower outcomes 2, 3. Fistula can be built over the entire body, 




Surgeons prefer to select the vessels at the most distal site available in the 
case of failing the first access and to preserve available sites for the future 
inquiry 1. Compared to the AV graft, AV fistulas exhibit higher patency 
although patency rates may differ among different research teams due to 
human factors involving surgical skills and patient pool categories 3. 
1.1.3 Arteriovenous Graft 
For most patients, AV fistula is an ideal method and it directly connects 
aforementioned vessels. It rarely induces inflammation and provides 
guaranteed safety as no foreign material is introduced 2. On the other hand, 
AV graft is utilized for the patients of whom the vessel is weakened by 
aging or a disease such as diabetes. Weak vessels are unable to withstand 
numerous needle punctures from a hemodialysis machine and thereby a 
graft is inserted in between the vein and the artery. The inlet and the outlet 
of the hemodialysis machine are then connected through the graft so it 
prevents the vessels to be worn. Therefore AV graft is preferred over fistula 
in the cases of such inquiry, however; it has been reported that AV graft can 
be more prone to infections and/or stenosis 4-6. Synthetic materials such as 
expanded polytetrafluoroethylene (ePTFE), silicon, or biological materials 
like homologous veins, bovine or sheep vessels may be used as grafts based 
on that as each material provides its own pros and cons 1. EPTFE is the most 
widely used material. In the USA, nearly 83% of the hemodialysis patients 




the upper arm in a straight or with a loop configuration. If the graft is placed 
in a loop, cautious observation is needed to avoid graft twisting or kinking. 
When complications take place, it is almost impossible to rescue graft and 
the graft should be eliminated surgically. Although failure of AV fistula in 
prior is irrelevant with the following graft failure, previous graft failure 
increases the risk of following graft failure substantially 2, 6. In this study, 
AV graft is used. 
1.2 .1 Complications 
Hemodynamic complications that may be arising from AV fistula and AV 
graft are stenosis and thrombosis, aneurysm formation, steal syndrome, 
ischemia, and heart failure. Non-hemodynamic complications include 
inflammations 2, 7. This study mainly deals with stenosis and inflammation 
complications. Effects of thrombosis is excluded using heparin solution 
which eliminates blood clots. For further information on symptoms unstated 
in detail, refer to: Radojica Stolic (2013) Med Princ Pract: 22. 
1.2.2 Stenosis 
Stenosis is a pathological condition of blood vessel narrowing. In AV fistula 
or graft, stenosis mostly occur in the anastomosis site and in the draining 
vein 8. This phenomenon can be reasoned by changes in of the flow property 
in the vein before and after the vascular access surgery. In the natural vein, 
blood pressure is relatively low at about 20 mmHg and blood flow is not 




upon vascular access creation, pressure mushrooms from 60 to 120 mmHg, 
flow is pulsatile, and wall shear stress becomes above 0.76 Pa1, 7. 
Neointimal hyperplasia is the underlying mechanism of stenosis. In order to 
understand the process of neointimal hyperplasia, the vein structure should 
be studied. The most inner layer is called the intima and it is consisted of a 
single layer of endothelial cells, the basement membrane, followed by the 
sub-endothelial matrix. In the sub-endothelial matrix, glycoproteins and 
connective tissue elements are in the upper layer. Tunica media is below the 
aforementioned layer and in tunica media, vascular smooth muscle cells 
(VSMC) reside. Adventitia is the thick outermost layer consisted of 
longitudinally oriented collagens and scattered fibroblasts 1, 2. During the 
formation of neointimal hyperplasia, VSMC in the tunica media migrate 
into the intima layer and it is considered neointimal hyperplasia is present 
when 20% of VSMC migrated into the intimal region, proliferated, and 
excreted extracellular matrix comprising 60-80% of the intima. Neointimal 
hyperplasia can be triggered by various aspects. It is initiated from injuries 
such as incisions from suturing. Factors like abnormal wall shear stress, 
high venous pressure, cyclic stretch, mismatch of elastic property between 
the vessel and the graft, and resultant angle between the vein and the graft 
can also elicit intima formation at various degrees 1-3, 7, 9. Stenosis formation 
may lead to thrombosis and it rises importance to catch it in the earlier stage. 
There is a higher risk of causing thrombosis as stenosis formation increases 




Peak systolic velocity in the Doppler spectrum is regarded as a fairly 
accurate parameter for detecting stenosis 10. If a degree of stenosis formation 
is severe, it should be treated to circumvent thrombosis occurrence. In order 
to remove stenosis, an inflatable balloon angioplasty is inserted to dilate the 
narrowed region. If the stenosis was removed inadequately, a stent is placed 
over an inflatable balloon and upon inflating, stent is widened and fitted to 
the diameter of the vessel. Nevertheless, restenosis occurrence is quite 
frequent spanning from 15 to 40%. If angioplasty treatment is insufficient, 
surgical removal is required 1-3, 10.  
1.3 .1 Factors developing Neointimal Hyperplasia 
Potentially there are several factors that may induce neointimal hyperplasia 
development such as increased turbulent flow, deficiency of endothelial 
cells, compliance mismatch between the native vessel and the graft, vessel 
damage, endothelial injury caused by high shear force, and growth factor 
release due to mechanical injury 1-3. 
1.3.2 Surgical Interventions 
As mentioned before, neointimal hyperplasia is developed most frequently 
at the anastomosis site and/or in the draining vein, especially along the 
suture line. Surgical trauma and the endothelial injury unquestionably 






1.4 .1 Anti-proliferative agent coating  
Anti-proliferative agent coating has been actively studied to reduce stenosis 
formation without surgical treatment. Its primary mechanism is to inhibit or 
to retard proliferation of the VSMC in the intima region. There are two 
types of anti-proliferative agent: rapamycin and paclitaxel. Rapamycin is 
known to inhibit interleukin-2 induced phosphorylation and activation of 
target kinases 11. In the case of paclitaxel, its main mechanism is to stabilize 
microtubules in the cytosol during the normal cell division. Both rapamycin 
and paclitaxel are regarded as the most effective agents aiming to inhibit 
stenosis by anti-proliferative roles. For such reason, they have been widely 
used for graft coating or other biomaterials such as stents in order to inhibit 
stenosis formation 12. However, previous studies, the randomized trial data, 
revealed that paclitaxel coated material is more effective than rapamycin 
coated one, and thence paclitaxel is selected for coating AV graft in this 
study 13. Up to date, many researches have proved that paclitaxel coated 
graft greatly retards neointimal tissue growth on the implantation site and 
remains the graft interior highly patent 14, 15. 
1.4.2 Foreign body response 
Previous studies have reported that paclitaxel localization on the outer 
surface of the graft may involve unwanted effects such as infections, 
seromas, pseudoaneurysms, or hematomas because of its toxic property that 




can develop an empty space between the surrounding tissue and the graft 16, 
17. Following the implantation, the interface between the material (e.g. graft) 
and the surrounding tissue is created. Upon material implantation and the 
associated injuries, inflammatory cascade and wound healing process are 
triggered. An inflammatory cascade is dependent on the exposure time of 
the material and it is a typical type of foreign body response. An acute phase 
and a chronic phase comprise the inflammatory cascade 18. During the acute 
phase lasting from hours to days, provisional matrix is formed and cleaning 
of the injury site by neutrophils takes place. Leukocytes adhere to the wall 
of a blood vessel to infiltrate and numerous tissue and blood proteins, such 
as growth factors and cytokines, are released. If the injury is not recovered 
and inflammatory phase is persistent, the chronic phase is followed 
gathering monocytes which differentiate into macrophages and lymphocytes. 
Blood vessels proliferate and connective tissue is reconstructed in the 
affected area to form granulation which then is replace by extracellular 
matrix in a normal wound healing process. However, the implanted material 
is too big for phagocytosis and frustrated macrophages fuse together to form 
a multinucleated giant cell around the material. In the end stage of the 
foreign body response, fibroblasts are called and blood vessels form to 
produce collagenous fibrous tissue and it completely walls of the material. 
As a result, interactions between the surrounding tissue and the material are 
prevented and the fibrous capsule containing the material, water, other 




1.5  Coating methods and previous studies 
Previous works have shown multiple ways coating AV grafts. Firstly, grafts 
were coated by dipping method. Dipping method is immersing a graft in a 
paclitaxel solution to coat. It is a cost-effective and facile way however; 
outer surface is also coated with paclitaxel which prevents cellular adhesion 
onto the surface. As continuous exposure of the surface of the graft due to 
paclitaxel may trigger the inflammatory cascade so paclitaxel-PLGA loading 
for sustained release was applied, however, animal experiments were not 
performed 21, 22. As stenosis formation at the anastomosis site had occurred 
within 3 cm, terminal coating method was followed 23. Tough it effectively 
reduced stenosis formation, still there was a chance of inflammation and 
thus, coating the inner surface of the graft to minimize poor prognosis was 
employed 16. Inner coating requires its own coating device which was 
manufactured manually. As paclitaxel solution is pumped up by a syringe 
pump pulsatily and a nozzle is moving for coating, uneven paclitaxel 
distribution was frequently observed. It has been proven that inner coating 
method exhibits higher affinity with the surrounding tissue and minimizes 
stenosis at the same time, however; more optimization is required to obtain 
even coating. Hence in this study, primary coating method is used to 
investigate the problematic inflammation degrees with different 
concentrations of paclitaxel which renders a good starting point to connect 




1.6  Research objective and clinical relevance 
So far, there is no information that deal with both level of patency and 
adverse side effects that may be accompanied by depending on different 
concentrations of paclitaxel. In addition, aside from grafts, there are 
numerous kinds of biomaterials eluting anti-proliferative agents such as 
paclitaxel or rapamycin. In previous studies, cyst formations were observed 
possibly due to adverse inflammatory responses in a porcine model. Also 
there were incidences of failure in clinical trial due to heavy inflammations 
while using an anti-proliferative drug eluting material. This study holds its 
clinical relevance in such a way that a close relationship is built between the 
level of stenosis and possible inflammatory responses. In this study, I utilize 
a dip coating method to coat whole ePTFE grafts with various 
concentrations of paclitaxel and investigate how they induce different fates 
spanning from stenosis reduction and/ or inflammation in a porcine model, 












Paclitaxel (Genexol® ) was purchased from Samyang Genex Inc, South 
Korea. The ePTFE vascular grafts (IMPRA, F4006C) were purchased from 
Bard Peripheral Vascular Inc, USA. High performance liquid 
chromatography (HPLC)-grade acetone and acetonitrile were obtained from 
Fisher Scientific, USA. Tween 20 was purchased from Sigma Cheminal Co, 
and phosphate-buffered saline (PBS) was obtained from Cambrex 
Corporation, USA.  
 
2.2 Preparation of paclitaxel-coated ePTFE grafts 
Paclitaxel-coated vascular grafts were made using a single dipping method. 
Briefly, paclitaxel was dissolved in acetone to a concentration of 0.25, 0.5, 
1.0, 2.0 or 4.0 mg/mL in polypropylene tubes, respectively. Each of the 
ePTFE vascular grafts, 6 mm in diameter and 20 cm long, was dipped into 
one of these solutions and incubated for 30 min at 37℃ in a roller incubator 
(Combi-H; FinePCR, Korea). The paclitaxel-coated ePTFE grafts were then 
air-dried and kept under vacuum overnight to remove the solvent completely. 
These grafts were sterilized in ethylene oxide gas before use. The 
corresponding amounts of paclitaxel on the grafts for the coating solution 
concentrations of 0.25, 0.5, 1.0, 2.0 or 4.0 mg/mL were 0.14, 0.28, 0.51, 




2.3 In vitro release test 
For the in vitro release test, PBS (pH 7.4) containing 0.05% (w/v) Tween-20 
was used as the drug release medium. Paclitaxel-coated vascular grafts with 
a length of 5 cm were soaked in polypropylene tubes with 8 mL of release 
medium and shaken at 37℃ and 20 rpm in a roller incubator. At designated 
time points over a period of 28 days, release medium was removed 
completely from the tubes and analyzed by HPLC (Agilent 1200 Series, 
USA) using a 4.6 x 150 mm C18 reverse-phase column and a UV detector 
set at 227 nm. HPLC analysis was performed using a mobile phase of water: 
acetonitrile (50:50 v/v) at a flow rate of 0.8 mL/min. Under these conditions, 
the peak of paclitaxel was eluted at 9.5 minutes. 
 
2.4 Experimental animals and operative technique 
25 female Landrace pigs, weighing 50 ± 7 kg, received one of six types of 
grafts between the common carotid artery and the external jugular vein: 
grafts without paclitaxel coating (control, n = 6); grafts with paclitaxel 
coating at a dose density of 0.14 g/mm2 (group 1, n = 4), 0.28 g/mm2 
(group 2, n = 4), 0.51 g/mm2 (group 3, n = 4), 1.11 g/mm2 (group 4, n = 
4) and 2.22 g/mm2 (group 5, n = 3). The animals were maintained in 
standard animal care facilities at Samsung Biomedical Research Institute 
(SBRI). This study was reviewed and approved by the Institutional Animal 




conformed to the Guidelines for the Care and Use of Laboratory Animals 
(NIH publication No. 85-23, revised 1996). 
Pigs were anesthetized with intramuscular ketamine HCl (20 mg/kg) and 
xylazine HCl (2 mg/kg). Then, they were incubated and ventilated with a 
mixture of O2 and air (1:2) containing isoflurane (2%) for maintenance 
anesthesia. Vecuronium bromide (0.1 mg/kg) was administered continuously 
through an ear vein. 
I adopted the animal model proposed by Rotmans et al. 25 Following 
standard surgical cleansing, a longitudinal incision was made in the lateral 
side of the neck along the sternocleidomastoid muscle. The common carotid 
artery and the external jugular vein were exposed and then heparin was 
given intravenously at 100 IU/kg before vessel manipulation. The common 
carotid artery was clamped using vessel loops and an 8-mm arteriotomy was 
made. An end-to-side anastomosis was made at approximately 45° using a 
6-0 polypropylene suture. Venous anastomoses were created in a similar 
manner. When the animals were euthanized at 6 weeks after operation, all 
the explantation process was done in anesthetized state. The implanted 
grafts were excised along with adjacent vessels, and immediately placed in 
heparin-containing PBS (10,000 IU/L), in order to remove the remaining 
blood from the vessel. From surgery day to the day of euthanasia, all pigs 
were administered aspirin (100 mg/day) and clopidogrel (PLAVIX® , Sanofi 





2.5 Paclitaxel amount in explanted graft  
In order to determine the amount of paclitaxel remaining in the graft 
implanted in a porcine for a 6-week-observation, the explanted graft was 
washed twice with normal saline and incubated in HPLC-grade methanol 
for 2 hours. The solution was then centrifuged down for 20 min and the 
supernatant was used for the analysis. 
 
2.6 Tissue preparation and morphometry 
The excised specimens were immersion fixed in 10% neutral-buffered 
formalin (NBF) for at least 24 h and embedded in paraffin. Sections (5 m) 
of veins 1-cm proximal and distal to anastomosis were prepared 
perpendicular to the blood flow. Serial sections were taken to obtain cross 
sections around the center of the graft–venous anastomosis, and three 
sections were analyzed in order to determine the percentage of luminal 
stenosis, as shown in Figure 1. 
All sections were stained with Masson Trichrome. The areas of intima and 
media could be manually traced on captured images obtained with an Aperio 
ImageScope (Aperio, USA). To compare stenosis among the control and 
paclitaxel-coated groups, the percentage of luminal stenosis was calculated 
from the area of neointima divided by the total luminal area inside grafts 
and vascular tissues. I measured the percentages of luminal stenoses in three 




values for these three sections were analyzed to compare between the 
groups. 
 
2.7 Immunohistochemical staining 
Sections (5 m) of paraffin-embedded tissues were immunostained with 
antibodies to alpha-smooth muscle actin (SMA; Abcam PLC, UK), vimentin 
(AbD Serotec, UK) and desmin (GeneTex, USA) using Vectastain ABC kits 
(Vector Laboratories, USA) according to the manufacturer’s instructions. 
Briefly, sections were deparaffinized and hydrated through a xylene and 
graded alcohol series. After antigen retrieval in antigen unmasking solution 
(Vector Laboratories) for 15 min, the slides were incubated in 0.3% H2O2 
for 30 min, in normal blocking serum for 20 min, in primary antibody 
overnight at 4 °C, in biotinylated secondary antibody for 30 min, in 
Vectastain ABC reagent for 30 min and in peroxidase substrate solution. The 
sections were then counterstained with hematoxylin, dehydrated through a 
graded alcohol series. To analyze cellular phenotypes for adjacent tissue 
outside the graft wall, semiquantitative scoring of all sections was 
performed on a scale from 0 to 4+, which corresponded to the percentage of 
positive cells for the specific marker in several different areas (0 = 0-10% 
positive; 1+ = 11-25% positive; 2+ = 26-50% positive; 3+ = 51-75% 






All data are presented as mean values ± the standard errors. Kruskal-Wallis 
tests were used to compare the percentages of luminal stenosis among 
groups; P<0.05 was considered statistically significant. I used SPSS 18.0 






















3.1.1 In vitro paclitaxel release profiles 
The in vitro drug release profiles for 28 days were measured to compare 
release patterns according to the coated amount of paclitaxel on the ePTFE 
grafts, as shown in Figure 2. A burst release of paclitaxel was followed by a 
slower sustained release, but less than 10% of the initial amount of the 
loaded drug was released after 28 days. Interestingly, in vitro release amount 
of paclitaxel tend to decrease significantly after sterilization with ethylene 
oxide gas, as in these case. 
3.1.2 In vivo paclitaxel release profiles 
During a 6-week-incubation, paclitaxel coated on the graft in group 1 and 
group 5 was all released by 99 % and 98 % respectively.  
3.2.1 Animal Experiments and histomorphometry 
I measured the luminal narrowing at the graft-venous anastomosis site.  
3.2.2 Percentage luminal stenosis  
As shown in Figure 3, pale blue regions were hyperplastic tissues in the 
inner vascular graft. The graft appeared to be a thick layer of red. Although 
lower venous region of cross-section was patent, the upper graft region 
might be entirely occluded. If the percentage of luminal stenosis at the graft-
venous anastomosis site was more than 50%, the blood flow was 
significantly reduced, and the middle region of implanted graft was often 




using a Doppler sonograph. Therefore, I considered that the implanted graft 
was occluded when the percentage of luminal stenosis was more than 50%. 
Depending on this assumption, five of the six control grafts were thought to 
be occluded even though the percentages of luminal stenosis were not 100%. 
Statistical values on % stenosis are listed in Table 1. If the luminal stenosis 
area occupies less than 50% of the total graft area in the cross section, the 
graft is regarded patent. Average % stenosis of the control group indicates 
few patency was observed while most of the grafts coated with paclitaxel 
exhibited ~100% patency. % Stenosis in group 5 was found to be the least 
whereas average % stenosis of group 1 to 4 lied within a moderate range 
from 14.5 - 21.3%. It should be noted that not all Pa values were less than 
0.05 due to small n numbers (n= 3-6) in comparison with control, thus I 
considered % stenosis of group 1 to 4 to be of similarity. As shown in Figure 
4, percentage of luminal stenosis drastically dropped from the control group 
to the ones coated with paclitaxel. Dash line indicated with * illustrates the 
mean values and only group 2 and 5 are statistically significant with 
unpaired Student’s t test. 
3.2.3 Thrombosis 
In 25 pigs including the control group, there was no case that was occluded 
due to thrombosis in this animal study. Therefore, I needed not to consider 
the influence of thrombosis to evaluate the percentage of luminal stenosis. 




excised ePTFE grafts and adjacent vessels were immediately placed in 
heparin-containing PBS (10,000 IU/L) to washout the remaining blood.  
3.2.4 Immunohistochemistry  
Immunohistochemistry for differentiating cellular types of the tissue 
surrounding the graft was performed. Three types of antibodies were 
employed to detect the type of cells as indicated in Table 2; a-SMA for 
detection of smooth muscle cells and myofibroblasts, vimentin for 
myofibroblasts and fibroblasts, and lastly desmin for smooth muscle cells 
only. Control group in the first row reveals high number of myofibroblasts 
and fibroblasts but relatively less amount of smooth muscle cells. In general, 
control group achieved successful tissue adhesion on to the graft. Group 2 
(0.51 ug/mm2) exhibits better tissue adhesion than Group 1 (0.14 ug/mm2) 
based on the number of cells stained. Group 3 (2.22 ug/mm2) scarcely 
retained any type of cells and poor tissue affinity on the graft was observed. 
It should be noted that the tissue affinity does not always decrease as the 
concentration of paclitaxel increases, which rises importance on adjusting 










Luminal neointimal tissue formation after implanting a graft is associated 
with multiple interactions among cellular components and non-cellular 
components such as vessel walls and blood 27. Such that, upon implantation, 
inflammatory reactions take place and excessive blood flow into the scarred 
region that a great number of migratory cells gather at the graft-venous site 
(Figure 1) 25, 27, 28. It has been widely studied with biomaterials coated with 
paclitaxel, e.g. stents or grafts as paclitaxel effectively enhances luminal 
patency and minimizes occlusion even at a low concentration 16, 29. In this 
work, effects of various doses of paclitaxel coated grafts on stenosis 
formation were compared and I found some interesting results 30, 31. I 
observed that paclitaxel coated grafts notably suppressed neointimal tissue 
formation and increased patency compared to the control group. There was 
not any apparent dose effect in the percentage of luminal stenosis among 
group 1-4 (0.14, 0.28, 0.51, 1.11 ug/mm2) as I acknowledge deviations 
considering small N number (Figure 3, Table 1). Albeit I found group 5 
(2.22 ug/mm2) with high dose paclitaxel most significantly inhibited 
stenosis in the graft, I also witnessed many cyst formations which informs 
us there was poor tissue affinity to the outer graft surface. In Figure 6, 
surrounding tissue of the graft was stained as a mean to differentiate cellular 
phenotypes with respective antibodies and Table 2 shows the presence of 




smooth muscle actin (α-SMA) and desmine, they appeared to be α-SMA-
positive/desmine-positive. Likewise, I may designate myofibroblasts and 
fibroblasts to be α-SMA-positive/vimentin-positive and vimentin-positive 
respectively. I found predominant cellular phenotypes of myofibroblasts and 
fibroblasts rather than smooth muscle cells in control group whereas 
increased number of smooth muscle cells and myofibroblasts were present 
in group 2 (0.28 ug/mm2). In group 3 (0.51 ug/mm2) and above, I found very 
weak staining and loss of detection in all cellular phenotypes owing to high 
level of paclitaxel 26. It should be noted that the data in Figure 2 should be 
not correlated to this result. When I see the release pattern in Figure 2, it 
seems the trend does not depend on the concentrations of paclitaxel such 
that I caught in Figure 6 because it is not biologically meaningful. 
Nevertheless, it allows us to understand the in vitro release pattern merely 
illustrates the burst release of paclitaxel in the beginning and the sustained 
release over a period of time. Though in reality, paclitaxel release happens 
fairly quickly during a systemic circulation and after a 6-week- period of 
incubation in vivo, almost all paclitaxel coated on the graft was released 
(Table 3) 32. Considering that, I speculate weak staining of group 3 and 
above (albeit not shown) is due to a foreign body response elicited by high 
concentration of paclitaxel. Vascular repair initially requires neointima 
formation and mostly smooth muscle cells play a major role in early 
thickening of neointima and in an acute injury, even many smooth muscle-




a key factor in wound healing process for their mechanical ability to provide 
contractibility and synthetic properties forming fibrosis. During the process, 
they migrate to the graft to deliver a contractile force suturing graft and 
tissue together for reconstruction 17, 20. Furthermore, adventitial fibroblasts 
also take part in the process as they go through phenotypic modulation to 
myofibroblasts upon vascular injury 17, 33. There is no surprise finding these 
cellular phenotypes in intima and in graft surrounding tissue and it explains 
why there was predominant presence of myofibroblasts and fibroblasts in 
the surrounding tissue of the control group as SMCs mostly reside in 
neointimal tissue for the aforementioned role of each phenotype. High dose 
paclitaxel release from the outer surface of the graft as well as the interior, 
however, impeded cell migration and infiltration onto the either surface 14, 34. 
Cellular adherence is thought to be one of the key steps in wound healing 
process and in the absence of rapid myofibroblasts infiltration, 
conspicuously few number of cells can exist on the outer graft, and it 
elongates exposure time of a bare graft triggering foreign body reactions 16, 
18, 19. Based on a time period, there are two types of inflammatory responses 
that can occur, comprising an acute phase in the beginning and a chronic 
phase subsequently 18, 35. Inflammatory phases largely depend on the size or 
degree of tissue injury. During the acute phase, from only hours to days, 
provisional matrix is formed and the wound site is cleaned up while 
fluid/proteins exudation and neutrophil attack occur. When excess amount 




blood/tissue proteins are released and leukocytes infiltrate the scarred region, 
followed by differentiation of monocytes into macrophages. If the body still 
senses the presence of foreign material until then, inflammation stage is 
transferred to a next chronic phase during which blood vessels proliferate 
and connective tissue restructures itself in the presence of macrophages and 
lymphocytes 18-20. Tissue granulation begins involving migration and 
proliferation of fibroblasts, and subsequent capillary formation. In the final 
step, a fibrous capsule is developed and it is often referred as a cyst 18, 19, 36. 
In this work, a few cyst formations were observed in group 3 and above. 
Especially group 5 involved 2 grafts completely separated from the 
surrounding tissue and the result is in agreement with the aforementioned 
weak staining. In sum, relatively low dose paclitaxel coated graft could 
markedly alter intimal response interior but high concentration of paclitaxel 
in return, displayed an adverse foreign body response 28. As histological 
findings showed, we would like to stress the point that low amount of 
paclitaxel coating on the graft greatly can enhance the level of patency and 










Herein, I demonstrated high concentration of paclitaxel coated ePTFE AV 
graft reduces stenosis caused by neointimal hyperplasia but it also promotes 
severe foreign body responses and tissue granulations leading to a cyst 
formation. Therefore, in order to achieve an optimal condition balancing 
two components, stenosis and a foreign body response, the relationship 
between the amount of an anti-proliferative agent released from the 
biomaterial and the severity of inflammation must be uncovered and 
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Figure 1. Diagrams of a graft-venous anastomosis. (A) Serial sections were 
taken to obtain cross sections around the center of the graft-venous 
anastomosis, and three of these sections were analyzed to find the mean 
percentage of luminal stenosis. One section was obtained at the center of the 
anastomosis; the others were obtained 2 mm to the proximal side and 2 mm 
to the distal side from the center of the anastomosis. (B) A cross-section was 
taken in the center of the anastomosis. The grey area indicates neointimal 









Figure 2. Cumulative in vitro release profiles from ePTFE grafts containing 
0.14, 0.28, 0.51, 1.11 and 2.22 ug/mm2 paclitaxel. Data are the means of 











Figure 3. Representative cross sections of graft-venous anastomosis from 
control grafts (A-B), and from paclitaxel-coated grafts of group 1 (C-D), 
group 2 (E-F), group 3 (G-H), group 4 (I-J) and group 5 (K-L), respectively. 
(Masson trichrome stain) Neointima can be recognized as pale blue stained 














Figure 4. Comparison of the percentage luminal stenosis among the control 
(n=6) and the paclitaxel-coated groups. * indicates the mean value of each 
group. Note that the differences between the control and paclitaxel-coated 








Figure 5. Comparison of luminal stenosis area (mm2). A decreasing trend 















Figure 6. The cellular phenotypes of surrounding tissue outside the grafts. 
The slide images show sequential sections of control (A-C), and paclitaxel-
coated grafts of group 1 (D-F), group 2 (G-I) and group 3 (J-L) 
immunohistochemically stained for alpha-SMA (A, D, G, J), vimentin (B, E, 










Percentage Luminal Stenosis 
(%) 
Patency Pa 
Control 76.7 ± 33.5 1 / 6  
Group 1  
(0.14 ug/mm2) 
14.5 ± 4.4 3 / 4 > 0.05 
Group 2  
(0.28 ug/mm2) 
10.9 ± 0.5 4 / 4 0.004 
Group 3  
(0.51 ug/mm2) 
18.0 ± 4.3 4 / 4 > 0.05 
Group 4  
(1.11 ug/mm2) 
21.3 ± 6.8 4 / 4 > 0.05 
Group 5  
(2.22 ug/mm2) 
5.9 ± 1.4 3 / 3 < 0.001 
 
Table 1. Morphometric data at the graft-venous anastomosis. The 
percentage of luminal stenosis is presented as mean ± standard error. 
Patency indicates the ratio of cross-sections which percentage luminal 






 α-SMA Vimentin Desmin 
Smooth muscle cells + - + 
Myofibroblasts + + - 
Fibroblasts - + - 
 
Table 2. Determining the cellular phenotypes through 
immunohistochemistry. If a cellular phenotype shows a positive reactions 























2.6 2.39 65.0 0.0020 99 
Group 5  
(2.22 ug/mm2) 
55.3 41.08 60.0 0.0400 98 
 
Table 3. Amount of paclitaxel remaining in the graft after a 6-week-
observation. One graft from each group 1 and 5 was used for analyzing the 
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DH1 × Slight swelling O 
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DH3 ○ Slight inflammation O 
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Severe swelling, dead. 
Hematoma was observed.  
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Abstract in Korean (국문 초록) 
 
신장 투석 환자들의 혈관 확보를 위해 동정맥루 (Arteriovenous 
graft)가 사용되는데 문합 부위를 중심으로 1~2 년 내로 발생하는 
위내막 과다형성 (Neointimal hyperplasia)에 의한 협착증 때문에 
혈관이 막히게 된다. 이를 방지하기 위해 위내막을 주로 형성하는 
평활근 세포들 (smooth muscle cells)의 증식을 억제시키는 
파클리탁셀이 널리 이용되고 돼지 실험을 통해 파클리탁셀이 
코팅된 인공혈관이 위내막 형성을 줄이고 높은 개통율에 
기여한다는 연구 결과가 있다. 위 논문에서는 여러 가지 코팅 
방법 중 비용, 시간, 균일성에 용이한 담금법 (dipping method)을 
사용 한다. 담금법을 사용하면 인공혈관의 양 면에 파클리탁셀이 
고루 도포되는데 바깥면에 코팅된 파클리탁셀은 고유의 항증식성 
성질로 혈관과 주변 조직 결합을 낮추어 이물 반응을 일으킬 수 
있고 심한 경우 혈관 주위로 낭종 (Cyst)이 형성되어 주변 조직과 
완전히 분리되게 된다. 이러한 이물 반응을 줄이고 개통율을 
높이기 위해 위 논문에서는 아래와 같은 농도; [Control (0 
ug/mm2), Group1 (0.14ug/mm2), Group2 (0.28ug/mm2), Group3 




파클리탁셀로 코팅된 인공혈관을 이용하여 농도 최적화를 
시도하였고, 그 결과 컨트롤은 심한 협착으로 혈관 막힘이 
보였으며, 0.14ug/mm2 에서는 75%의 개통율을, 
0.28ug/mm2 이상에서 100%의 개통율과 낮은 위내막 형성이 관찰 
되었지만 0.51ug/mm2 이상부터 이물반응으로 인한 감염과 낭종이 
발견되었다. 그러므로 낮은 농도 (0.28ug/mm2)로 담금법 코팅을 
할 경우 주변 조직과 혈관의 결합에 해를 가하지 않고 이물 
반응을 일으키지 않는 선에서 위내막 형성을 최소화하여 개통율을 
높일 수 있다.  
주요어: 파클리탁셀, 동정맥루, 위내막 과다형성, 이물반응, 개통율, 
신장 투석 
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